{"id":542208,"date":"2021-05-07T14:04:01","date_gmt":"2021-05-07T14:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542208"},"modified":"2021-05-07T14:04:01","modified_gmt":"2021-05-07T14:04:01","slug":"acute-kidney-injury-aki-market-size-and-share-trends-epidemiology-and-market-forecast-report-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-kidney-injury-aki-market-size-and-share-trends-epidemiology-and-market-forecast-report-2030-delveinsight_542208.html","title":{"rendered":"Acute Kidney Injury (AKI) Market Size and Share, Trends, Epidemiology and Market Forecast Report 2030 | DelveInsight"},"content":{"rendered":"
\"Acute<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cAcute Kidney Injury (AKI) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Acute Kidney Injury (AKI), historical and forecasted epidemiology as well as the Acute Kidney Injury (AKI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\n<\/div>\n

DelveInsight has launched a new report on “Acute Kidney Injury (AKI) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>.<\/span><\/p>\n

 <\/p>\n

DelveInsight’s<\/span> “Acute Kidney Injury (AKI) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″<\/span> report delivers an in-depth understanding of the Acute Kidney Injury (AKI), historical and forecasted epidemiology as well as the Acute Kidney Injury (AKI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    The highest incident cases of Acute Kidney Injury (AKI) were recorded in the United States which was 895,078 in 2017.<\/span><\/p>\n<\/li>\n

  2. \n

    Among the EU5 countries, Germany had the highest AKI diagnosed discharge cases with 82,902 cases followed by France while the least number of cases were observed in Spain in 2017.<\/span><\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/span><\/strong><\/p>\n

    1. Acute Kidney Injury (AKI) market report covers a descriptive overview and comprehensive insight of the Acute Kidney Injury (AKI) epidemiology and Acute Kidney Injury (AKI) market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span><\/p>\n

    2. Acute Kidney Injury (AKI) market report provides insights on the current and emerging therapies.<\/span><\/p>\n

    3. Acute Kidney Injury (AKI) market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span><\/p>\n

    4. Acute Kidney Injury (AKI) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Kidney Injury (AKI) market.<\/span><\/p>\n

    Request for sample pages<\/span>:<\/span> https:\/\/www.delveinsight.com\/sample-request\/acute-kidney-injury-aki-market<\/span><\/a><\/strong><\/span><\/strong><\/p>\n

    Acute Kidney Injury (AKI): Overview<\/span><\/strong><\/p>\n

    Acute kidney injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in your blood and makes it hard for your kidneys to keep the right balance of fluid in your body. AKI can also affect other organs such as the brain, heart, and lungs. Acute kidney injury is common in patients who are in the hospital, in intensive care units, and especially in older adults.<\/span><\/p>\n

    The key player involved in Acute Kidney Injury (AKI) market:<\/span><\/strong><\/a><\/p>\n

      \n
    1. \n

      Angion Biomedica<\/span><\/p>\n<\/li>\n

    2. \n

      Quark Pharmaceutical <\/span><\/p>\n<\/li>\n

    3. \n

      Astellas Pharma<\/span><\/p>\n<\/li>\n

    4. \n

      MediBeacon<\/span><\/p>\n<\/li>\n

    5. \n

      Pharming Technologies <\/span><\/p>\n<\/li>\n

    6. \n

      AM Pharma<\/span><\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the Acute Kidney Injury (AKI) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drugs covered<\/span><\/strong><\/p>\n

        \n
      1. \n

        ANG-3777 or BB3<\/span><\/p>\n<\/li>\n

      2. \n

        QPI-1002<\/span><\/p>\n<\/li>\n

      3. \n

        ASP1128<\/span><\/p>\n<\/li>\n

      4. \n

        MB-102<\/span><\/p>\n<\/li>\n

      5. \n

        Ruconest (Conestat alfa) <\/span><\/p>\n<\/li>\n

      6. \n

        recAP<\/span><\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/acute-kidney-injury-aki-market<\/span><\/a><\/span><\/strong><\/p>\n

        Table of Contents<\/span><\/strong><\/p>\n

        1. Report Introduction<\/span><\/p>\n

        2. Executive Summary<\/span><\/p>\n

        3. SWOT analysis<\/span><\/p>\n

        4. Acute Kidney Injury (AKI) Patient Share (%) Overview at a Glance<\/span><\/p>\n

        5. Acute Kidney Injury (AKI) Market Overview at a Glance<\/span><\/p>\n

        6. Acute Kidney Injury (AKI) Disease Background and Overview<\/span><\/p>\n

        7. Acute Kidney Injury (AKI) Epidemiology and Patient Population<\/span><\/p>\n

        8. Country-Specific Patient Population of Acute Kidney Injury (AKI)<\/span><\/p>\n

        9. Acute Kidney Injury (AKI) Current Treatment and Medical Practices<\/span><\/p>\n

        10. Unmet Needs<\/span><\/p>\n

        11. Acute Kidney Injury (AKI) Emerging Therapies<\/span><\/p>\n

        12. Acute Kidney Injury (AKI) Market Outlook<\/span><\/p>\n

        13. Country-Wise Acute Kidney Injury (AKI) Market Analysis (2017–2030)<\/span><\/p>\n

        14. Market Access and Reimbursement of Therapies<\/span><\/p>\n

        15. Market drivers<\/span><\/p>\n

        16. Market barriers<\/span><\/p>\n

        17. Appendix<\/span><\/p>\n

        18. Acute Kidney Injury (AKI) Report Methodology<\/span><\/p>\n

        19. DelveInsight Capabilities<\/span><\/p>\n

        20. Disclaimer<\/span><\/p>\n

        21. About DelveInsight<\/span><\/p>\n

        Related Reports:<\/span><\/strong><\/p>\n

        Acute Kidney Injury (AKI) – Pipeline Insights, 2021<\/span><\/strong><\/p>\n

        “<\/span>Acute Kidney Injury (AKI) Pipeline Insight, 2020<\/span>” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Acute Kidney Injury (AKI) market. A detailed picture of the Acute Kidney Injury (AKI) pipeline landscape is provided, which includes the disease overview and Acute Kidney Injury (AKI) treatment guidelines.<\/span><\/p>\n

        Acute Kidney Injury (AKI) – Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘<\/span>Acute Kidney Injury (AKI) – Epidemiology Forecast to 2030<\/span>‘ report delivers an in-depth understanding of the disease, historical and forecasted Acute Kidney Injury (AKI) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cAcute Kidney Injury (AKI) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Acute Kidney Injury (AKI), historical and forecasted epidemiology as well as the Acute Kidney Injury (AKI) market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,417,404],"tags":[],"class_list":["post-542208","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Marketing-Sales","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542208"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542208\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}